These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7553660)

  • 1. Are CD44 variant isoforms involved in human tumour progression?
    Günthert U; Stauder R; Mayer B; Terpe HJ; Finke L; Friedrichs K
    Cancer Surv; 1995; 24():19-42. PubMed ID: 7553660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
    Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
    Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
    Terpe HJ; Störkel S; Zimmer U; Anquez V; Fischer C; Pantel K; Günthert U
    Am J Pathol; 1996 Feb; 148(2):453-63. PubMed ID: 8579108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
    Fichtner I; Dehmel A; Naundorf H; Finke LH
    Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas.
    Terpe HJ; Koopmann R; Imhof BA; Günthert U
    J Pathol; 1994 Oct; 174(2):89-100. PubMed ID: 7525912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter.
    Masuda M; Takano Y; Iki M; Makiyama K; Noguchi S; Hosaka M
    J Urol; 1999 Mar; 161(3):805-8; discussion 808-9. PubMed ID: 10022688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 is an independent prognostic factor in conventional renal cell carcinomas.
    Paradis V; Ferlicot S; Ghannam E; Zeimoura L; Blanchet P; Eschwége P; Jardin A; Benoît G; Bedossa P
    J Urol; 1999 Jun; 161(6):1984-7. PubMed ID: 10332486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
    Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
    Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
    Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
    Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
    Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
    Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CD44 molecule in renal cell carcinoma.
    Lucin K; Matusan K; Dordević G; Stipić D
    Croat Med J; 2004 Dec; 45(6):703-8. PubMed ID: 15578803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type.
    Ariza A; Mate JL; Isamat M; López D; Von Uexküll-Güldeband C; Rosell R; Fernández-Vasalo A; Navas-Palacios JJ
    J Pathol; 1995 Dec; 177(4):363-8. PubMed ID: 8568590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers.
    de la Torre M; Heldin P; Bergh J
    Anticancer Res; 1995; 15(6B):2791-5. PubMed ID: 8669866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44 splice variants: expression during lymphocyte activation and tumor progression.
    Pals ST; Koopman G; Heider KH; Griffioen A; Adolf GR; Van den Berg F; Ponta H; Herrlich P; Horst E
    Behring Inst Mitt; 1993 Aug; (92):273-7. PubMed ID: 7504454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression.
    Li H; Guo L; Li JW; Liu N; Qi R; Liu J
    Int J Oncol; 2000 Nov; 17(5):927-32. PubMed ID: 11029494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44.
    Saleh F; Reno W
    Neoplasma; 2008; 55(3):246-55. PubMed ID: 18348657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas.
    Satoh K; Shimosegawa T; Koizumi M; Toyota T
    Anticancer Res; 1997; 17(1A):215-9. PubMed ID: 9066654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
    Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
    J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.